Pfizer stock jumps 14% as TrumpRx drug pricing deal eases tariff fears

Pfizer reached a voluntary agreement with the Trump administration on September 30, 2025, to cut prescription drug costs for American patients by matching prices in other developed countries and offering discounts up to 85% via a forthcoming federal platform, TrumpRx.gov, while committing $70 billion to U.S.-based R&D and manufacturing in exchange for a three-year tariff grace period.

Investors saw the deal as a signal that tariff threats could ease across the sector, sparking a relief rally. Pfizer shares closed up 6.8% at $25.48 on September 30, marking the stock’s best day since October 2021. In late-day trading on October 1, the stock surpassed $27 per share, up $27.28 by Oct. 1. That’s a 14.2% gain in two trading days. in two trading days.

Broader biopharma stocks followed suit on expectations of similar deals for other firms, as Trump said more agreements are coming.

Officials and the company also said newly launched Pfizer medicines will be introduced in the U.S. at Most-Favored Nations (MFN) levels, no higher than prices in other advanced economies with administration statements specifying that those MFN terms extend across Medicare, Medicaid and commercial coverage.

How the MFN framework works

The agreement operates on two tracks. For Pfizer’s existing drug portfolio, MFN pricing applies to Medicaid beginning in 2026. For future launches, Pfizer commits to introducing new medicines at MFN pricing across all payers: Medicare, Medicaid and commercial insurers, addressing a gap in prior pricing reform efforts by ensuring new innovations debut at internationally benchmarked prices from day one.

The White House fact sheet declares: “The agreement ensures foreign nations can no longer use price controls to freeride on American innovation by guaranteeing MFN prices on all new innovative medicines Pfizer brings to market. ”

White House materials and follow-on coverage highlighted several initial cash-pay examples planned for TrumpRx.gov. Pfizer and officials say ranges will vary by product, with an average discount near 50% and some as high as 85%. (See the table below.)

Timing, tariffs and scope

The administration targets an early 2026 rollout for TrumpRx.gov. The White House and Pfizer said the company will receive a three-year grace period from new pharmaceutical tariffs, contingent on ramping U.S. production and investment; officials had previously pointed to October 1, 2025 as the start for proposed 100% tariffs absent cooperation.

Investors read the package as manageable near-term: Pfizer shares rose roughly 6.8% on Sept. 30, with gains continuing to 7.2% by midday Oct. 1, as broader biopharma rallied on expectations that the immediate scope centers on Medicaid and a limited DTC channel.

What drove the rally

The sharp stock gain reflects investor relief on two fronts. First, the tariff exemption removes immediate uncertainty around potential 100% levies on pharmaceutical imports that were set to begin October 1. Second, analysts noted that limiting price concessions primarily to Medicaid, which represents only about 5% of Pfizer’s U.S. sales, keeps the revenue impact modest while delivering political wins for the administration.

Broader biopharma stocks rose in sympathy, with Eli Lilly up 5%, AbbVie climbing 3%, and other major drugmakers posting gains as markets anticipated similar deals industry-wide.

Examples of listed discounts

The White House and Pfizer provided initial examples of drugs that will be available through TrumpRx.gov at steep cash-pay discounts:

TrumpRx.gov is a cash-pay channel; insured out-of-pocket costs could still be lower depending on coverage. Full SKU-level price lists, eligibility rules and refill logistics have not yet been published.

Glossary

Most-favored-nation (MFN) pricing: A benchmark pegging U.S. prices to the lowest net price in a basket of comparable countries. In this deal, Medicaid gets MFN on existing drugs in 2026; new Pfizer drugs launch at MFN levels across payers.

DTC (direct-to-consumer) channel: A pathway for patients to buy medicines for cash, outside insurance, at posted discounts.

Section 232 tariffs: National-security-based tariffs applied to imported branded drugs; Pfizer has a three-year exemption while expanding U.S. production.